Description
Developer of pharmaceutical products designed to treat ocular diseases. The company's products are developed with pre-clinical research and lead selection, enabling healthcare practitioners to treat rare diseases, including ocular trauma and other eye diseases.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Early Stage VC | 31-Jan-2017 | $80K | 00000 | Completed | Generating Revenue | |
1. Early Stage VC | 14-Aug-2013 | 00000 | 00000 | Completed | Generating Revenue |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Gary Prosterman | Treasurer & Board Member | ||
Raymond Hage Jr. | President & Board Member | ||
Edward Chaum MD | Co-Founder & Chief Scientific Officer |
Name | Representing | Role | Since |
---|---|---|---|
Gary Prosterman | Focal Point Pharmaceuticals | Treasurer & Board Member | 000 0000 |
Gary Stevenson | MB Venture Partners | Board Member | 000 0000 |
Raymond Hage Jr. | Self | President & Board Member | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
MB Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 |